Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure

  • End date
    Jul 28, 2021
  • participants needed
  • sponsor
    American University of Beirut Medical Center
Updated on 28 January 2021
semen analysis
in vitro fertilization
embryo transfer
intracytoplasmic sperm injection


The objective of this study is to determine the effect of Bemiparin, a low molecular weight heparin, on implantation rate in women with unexplained recurrent implantation failure undergoing IVF/ICSI treatment.


Recurrent implantation failure (RIF), defined as failure of conception following three or more consecutive In Vitro Fertilization (IVF) cycles despite the transfer of good quality embryos, is a major cause of distress amongst infertile couples. While factors underlying implantation failure are many, most cases remain unexplained. In order to improve pregnancy outcomes and delivery rates in women with unexplained RIF, various investigational treatments have been proposed.

The investigators propose a prospective controlled randomized comparative study to evaluate the effect of Bemiparin on implantation rates in women with unexplained RIF. A total of 200 patients will be recruited and randomized between two groups. The study group will receive Bemiparin plus standard care; while the control group will receive only standard care. Treatment will start on the day following embryo transfer and will be continued until 12 weeks gestation in the event of pregnancy.

The primary objective is to determine the effect of Bemiparin on implantation rate in women with unexplained recurrent implantation failure.

Condition Female Genital Diseases, Infertility, Gynecological Infections, sterility, unable to conceive
Treatment Bemiparin sodium
Clinical Study IdentifierNCT02607319
SponsorAmerican University of Beirut Medical Center
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 38 yrs?
Are you female?
Do you have Infertility?
Do you have any of these conditions: unable to conceive or Gynecological Infections or sterility or Female Genital Diseases or Infertility?
History of three or more consecutively failed In Vitro Fertilization (IVF) cycles after embryo transfer
Normal uterine cavity (as assessed by hysteroscopy or HSG)
Normal hormonal investigation: TSH, PRL, FBS
Normal acquired/inherited thrombophilia profile: LAC, ACA IgG/IgM, Prot S, Antithrombin III, beta-2 glycoprotein, Factors V, II, MTHFR
Normal semen analysis and mild/moderate male factor (Total motile sperm count > 5 million/ml and/or normal WHO morphology >20%
Patient provides written informed consent

Exclusion Criteria

Evidence of low ovarian reserve by at least one of the following: AMH 1,5 ng/mL and/or basal CD 3 FSH 10 mIU/mL and/or basal CD 3 Estradiol 60 ng/mL and/or previous egg collection yield 3 oocytes
Preexisting medical condition (thyroid disease, diabetes mellitus, hypertension, pulmonary conditions, cardiac condition)
Severe male factor infertility (Total motile sperm count < 5 million/ml and/or normal WHO morphology <20%)
Hypersensitivity to Heparin or its derivatives
Acquired thrombophilia
Active hemorrhage or increased risk of bleeding due to impairment of homeostasis
Severe impairment of liver or pancreatic function
Severe renal insufficiency (Creatinine Clearance < 30 ml/min)
Injuries to or operations on the central nervous system, eyes and ears within the last 2 months
Disseminated Intravascular Coagulation (DIC) attributable to heparin-induced thrombocytopenia
Acute bacterial endocarditis and endocarditis lenta
Any organic lesion with high risk of bleeding (e.g.: active peptic ulcer, hemorrhagic stroke, cerebral aneurysm or cerebral neoplasms)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note